Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04617015 · ClinicalTrials.gov registry record · Early Phase 1
Defining and Treating Depression-related Asthma
A Early Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT04617015: Completed Early Phase 1 study, sponsored by State University of New York at Buffalo.
NCT04617015 is a Early Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 39 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04617015, a Early Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression. The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.
Primary Outcome
difference between lung function (FEV1) measurement from baseline to 30 minutes post ipratropium This measure was calculated using the formula: (Post-ipratropium value - baseline value) / baseline value x100
Interventions
- DRUG Ipratropium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-09-09 |
| Est. Completion | 2019-03-11 |
| Phase | Early Phase 1 |
What the finished NCT04617015 record still lists
NCT04617015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 1 intervention - of which Ipratropium Bromide is the first listed.
NCT04617015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04617015 about?
NCT04617015 is a clinical study titled "Defining and Treating Depression-related Asthma". Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depressio...
What is the current status of trial NCT04617015?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2016-09-09. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT04617015?
The interventions under investigation include: Ipratropium Bromide (DRUG).
Who is sponsoring clinical trial NCT04617015?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04617015's enrollment target sits among peer trials
39 689th of 2000 higher than 1,303 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI